Singapore, March 28 -- Australian biotech firm CSL recently celebrated the official opening of the company's new state-of-the-art research and development (R&D) centre in Waltham, Massachusetts, US.

The custom-built facility is approximately 140,000 square feet with 54,000 square feet of lab space, including the first biosafety level 3 laboratory (BSL-3) in Waltham. The site will serve as CSL's central hub for current and future vaccine design.

CSL's global Research and Development organisation has more than 2,000 employees in ten countries around the world, contributing to a robust and promising pipeline of novel therapeutic candidates. In addition to Waltham, Massachusetts, the company has an R&D presence in King of Prussia, Pennsylva...